PAA
LGND icon

Peregrine Asset Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Peregrine Asset Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,366
Closed -$228K – 107
2015
Q4 		$228K Buy
+3,366
New +$208K 0.2% 78
2015
Q3 		– Sell
-3,366
Closed -$212K – 100
2015
Q2 		$212K Buy
+3,366
New +$184K 0.16% 99

Other funds holding LGND

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Peregrine Asset Advisers's LGND Position: Q1 2016 in Review

Peregrine Asset Advisers sold out of Ligand Pharmaceuticals (LGND) in Q1 2016, closing a stake of 3,366 shares — an estimated $228K sold.

Peregrine Asset Advisers first reported a position in LGND in Q2 2015 and held it in 2 quarters. The position peaked at $228K in Q4 2015. 251 funds tracked by Wall St. Rank hold LGND as of Q1 2016.

  • Peregrine Asset Advisers reported no remaining Ligand Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Peregrine Asset Advisers sold 3,366 Ligand Pharmaceuticals shares in Q1 2016, an estimated $228K.
  • Peregrine Asset Advisers first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Peregrine Asset Advisers's Ligand Pharmaceuticals position peaked at $228K in Q4 2015.
  • 251 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2016.

Based on Peregrine Asset Advisers's 13F filing for Q1 2016, filed 13 May 2016.